OrbiMed Closes A $950m Fund As Biotech VC Surge Continues
This article was originally published in Scrip
The health care-focused venture capital firm OrbiMed has raised its largest VC fund to date totaling $950m and if prior investment patterns are repeated as much as $760m of that could be invested in companies focused on the development of drugs or gene therapies.
You may also be interested in...
The firm's $38.6m in Series C cash will fund additional clinical trials for lead translation regulator eFT508, support the first human trial for eFT226 and advance a third program into preclinical studies.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.